FINNENCE▪
00:00:00 UTCSYS ONLINE
FINNENCE ▪ THE WIRE FILE

THE WIRE · № 69050

News▼ Bearish

Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets

EXHIBIT · mmx.prnewswire.com
KINDNews
DIRECTION▼ Bearish
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-07 12:30 UTC
LAST UPDATE2026-10-07 12:30 UTC
STATEactive

01 THE MACHINE READ

WHY IT MATTERS.

An injunction blocking Keytruda SC in European markets threatens Merck revenue and validates Halozyme's patent position.

Halozyme wins EU injunction against Merck
CATALYST TO WATCH

Merck appeal or settlement talks

MAIN RISK

Ruling may be overturned on appeal

FULL DISPATCH

SAN DIEGO, Oct. 7, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") announced today that the specialized Dutch patent court of the Hague has found Merck to be infringing one of its MDASE patents, EP 2,797,622 (EP622) and ordered Merck's central...

02 THE STORY SO FAR

THE RECORD, IN ORDER.

STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.

03 WHO'S INVOLVED

ENTITIES ON FILE.

AFFECTEDHealthcare

04 RECEIPTS

THE SOURCE RECORD.

1 SOURCES CONFIRMED
№ 01prnewswireprnewswire.com · PRIMARY2026-10-07 12:30 UTCOPEN RECEIPT →

05 PROPAGATION

WHAT THIS TOUCHES.

KEEP READING THE MACHINE

OPEN THE MACHINE →THE PREDICTION LEDGER →

Summaries are generated and may contain errors — every claim links its sources.